WINT
Windtree Therapeutics, Inc.
Price Chart
Latest Quote
$0.02
Current Price| Previous Close | $0.02 |
| Open | $0.02 |
| Day High | $0.02 |
| Day Low | $0.02 |
| Volume | 50,108 |
Stock Information
| Shares Outstanding | 33.71M |
| Total Debt | $3.48M |
| Cash Equivalents | $204K |
| Net Income | $-48.83M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $512K |
| P/E Ratio | 0.00 |
| EPS (TTM) | $323.08 |
| Exchange | PNK |
📊 Custom Metrics & Score
Score: 8/42| Debt to Equity | 0.18 |
| Debt to Earnings | -1.02 |
| Current Ratio | 0.45 |
| Quick Ratio | 0.31 |
| Return on Equity | -17.88% |
| Avg FCF Growth | -8.91% |
| FCF Yield | -3008.36% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.02 | 270,800 |
| 2026-01-30 | $0.02 | 133,700 |
| 2026-01-29 | $0.02 | 1,289,300 |
| 2026-01-28 | $0.02 | 30,100 |
| 2026-01-27 | $0.02 | 111,700 |
| 2026-01-26 | $0.02 | 271,300 |
| 2026-01-23 | $0.02 | 224,000 |
| 2026-01-22 | $0.02 | 337,800 |
| 2026-01-21 | $0.02 | 1,476,700 |
| 2026-01-20 | $0.02 | 25,400 |
| 2026-01-16 | $0.02 | 575,500 |
| 2026-01-15 | $0.02 | 296,900 |
| 2026-01-14 | $0.02 | 733,400 |
| 2026-01-13 | $0.02 | 300,000 |
| 2026-01-12 | $0.02 | 577,800 |
| 2026-01-09 | $0.03 | 353,500 |
| 2026-01-08 | $0.03 | 309,300 |
| 2026-01-07 | $0.03 | 633,400 |
| 2026-01-06 | $0.03 | 252,600 |
| 2026-01-05 | $0.03 | 582,100 |
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
📰 Latest News
Nasdaq Boots Windtree a Month After $700M BNB Treasury Pivot Fails to Lift Stock
decrypt • 2025-08-21T02:33:08Z
BNB treasury company faces delisting from Nasdaq on Aug. 21
CryptoSlate • 2025-08-20T22:43:26Z
BNB Climbs Above $810 as Buyers Target $815 Resistance
CoinDesk • 2025-08-12T15:17:27Z
BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism
CoinDesk • 2025-08-05T16:11:49Z
BNB Rises Over 6% Amid U.S.-EU Trade Deal and $610M Corporate Buying
CoinDesk • 2025-07-28T12:15:55Z
BNB Rebounds to $780 After $520M Windtree Buy Commitment, Shows Signs of Stabilizing
CoinDesk • 2025-07-26T17:31:33Z
Why Are Public Companies Amassing ETH, XRP, SOL, BNB Instead Of Just Bitcoin?
Benzinga • 2025-07-25T13:29:28Z
Kraken to Support Biotech Firm Windtree’s $200M BNB Treasury Play
CoinDesk • 2025-07-22T15:15:40Z
BNB Rises as Binance Dominates Q2 Volumes, Windtree Unveils $200M Treasury
CoinDesk • 2025-07-18T11:54:30Z
BC-Most Active Stocks
Associated Press Finance • 2025-07-17T14:30:17ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $235,000 | $50,000 | $53,000 | $114,000 |
| Total Expenses | $25,019,000 | $17,539,000 | $21,889,000 | $32,260,000 |
| Other Income Expense | $23,391,000 | $-3,027,000 | $-18,742,000 | $-45,340,000 |
| Other Non Operating Income Expenses | $-408,000 | $31,000 | $2,000 | $-320,000 |
| Net Non Operating Interest Income Expense | $-165,000 | $275,000 | $56,000 | $-23,000 |
| Interest Expense Non Operating | $235,000 | $50,000 | $53,000 | $114,000 |
| Operating Expense | $25,019,000 | $17,539,000 | $21,889,000 | $32,260,000 |
| General And Administrative Expense | $8,743,000 | $9,198,000 | $10,790,000 | $14,473,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-1,787,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Net Interest Income | $-165,000 | $275,000 | $56,000 | $-23,000 |
| Interest Income | $70,000 | $325,000 | $109,000 | $91,000 |
| Normalized Income | $-25,506,360 | $-17,233,000 | $-21,095,498 | $-28,408,288 |
| Net Income From Continuing And Discontinued Operation | $-1,787,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Total Operating Income As Reported | $-26,139,000 | $-20,597,000 | $-41,333,000 | $-77,280,000 |
| Net Income Common Stockholders | $-5,487,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Net Income | $-1,787,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Net Income Including Noncontrolling Interests | $-1,787,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Net Income Continuous Operations | $-1,787,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Pretax Income | $-1,793,000 | $-20,291,000 | $-40,575,000 | $-77,623,000 |
| Special Income Charges | $13,317,000 | $-3,058,000 | $-19,444,000 | $-45,020,000 |
| Interest Income Non Operating | $70,000 | $325,000 | $109,000 | $91,000 |
| Operating Income | $-25,019,000 | $-17,539,000 | $-21,889,000 | $-32,260,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-104.35 | $-4718.84 | $-56007.00 | $-107700.64 |
| Basic EPS | $-104.35 | $-4718.84 | $-45696.97 | $-107700.64 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $79,640 | $0 | $-631,498 | $-5,792,288 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-25,273,000 | $-17,101,000 | $-21,245,000 | $-32,297,000 |
| Total Unusual Items | $23,799,000 | $-3,058,000 | $-18,744,000 | $-45,020,000 |
| Total Unusual Items Excluding Goodwill | $23,799,000 | $-3,058,000 | $-18,744,000 | $-45,020,000 |
| Reconciled Depreciation | $84,000 | $82,000 | $533,000 | $192,000 |
| EBITDA (Bullshit earnings) | $-1,474,000 | $-20,159,000 | $-39,989,000 | $-77,317,000 |
| EBIT | $-1,558,000 | $-20,241,000 | $-40,522,000 | $-77,509,000 |
| Diluted Average Shares | $52,583 | $4,300 | $858 | $628 |
| Basic Average Shares | $52,583 | $4,300 | $858 | $628 |
| Diluted NI Availto Com Stockholders | $-5,487,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Preferred Stock Dividends | $3,700,000 | - | - | - |
| Tax Provision | $-6,000 | $0 | $-1,367,000 | $-9,987,000 |
| Other Special Charges | $-14,437,000 | - | - | - |
| Impairment Of Capital Assets | $1,120,000 | $3,058,000 | $19,444,000 | $45,020,000 |
| Gain On Sale Of Security | $10,482,000 | - | $700,000 | - |
| Research And Development | $16,276,000 | $8,341,000 | $11,099,000 | $17,787,000 |
| Selling General And Administration | $8,743,000 | $9,198,000 | $10,790,000 | $14,473,000 |
| Other Gand A | $8,743,000 | $9,198,000 | $10,790,000 | $14,473,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-14,134,000 | $-21,859,000 | $-18,296,000 | $-5,871,000 |
| Total Assets | $27,875,000 | $32,406,000 | $37,954,000 | $74,789,000 |
| Total Non Current Assets | $25,301,000 | $27,027,000 | $30,577,000 | $51,298,000 |
| Other Non Current Assets | $9,000 | $150,000 | $154,000 | $154,000 |
| Goodwill And Other Intangible Assets | $24,130,000 | $25,250,000 | $28,308,000 | $47,752,000 |
| Other Intangible Assets | $24,130,000 | $25,250,000 | $25,250,000 | $32,070,000 |
| Current Assets | $2,574,000 | $5,379,000 | $7,377,000 | $23,491,000 |
| Other Current Assets | $795,000 | $1,060,000 | $1,205,000 | $1,143,000 |
| Cash Cash Equivalents And Short Term Investments | $1,779,000 | $4,319,000 | $6,172,000 | $22,348,000 |
| Cash And Cash Equivalents | $1,779,000 | $4,319,000 | $6,172,000 | $22,348,000 |
| Prepaid Assets | - | - | - | $1,143,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $1,822,000 | $1,830,000 | $2,280,000 | $2,893,000 |
| Long Term Debt And Capital Lease Obligation | $653,000 | $1,161,000 | $1,624,000 | $2,071,000 |
| Current Debt And Capital Lease Obligation | $1,169,000 | $669,000 | $656,000 | $822,000 |
| Current Debt | $661,000 | $233,000 | $252,000 | $294,000 |
| Other Current Borrowings | $333,000 | $233,000 | $252,000 | $294,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $17,879,000 | $29,015,000 | $27,942,000 | $32,908,000 |
| Total Non Current Liabilities Net Minority Interest | $12,162,000 | $25,019,000 | $25,485,000 | $27,985,000 |
| Other Non Current Liabilities | $3,800,000 | $18,800,000 | $18,800,000 | $18,800,000 |
| Non Current Deferred Liabilities | $4,528,000 | $5,058,000 | $5,061,000 | $7,114,000 |
| Non Current Deferred Taxes Liabilities | $4,528,000 | $5,058,000 | $5,061,000 | $7,114,000 |
| Current Liabilities | $5,717,000 | $3,996,000 | $2,457,000 | $4,923,000 |
| Other Current Liabilities | $963,000 | $900,000 | - | - |
| Current Notes Payable | $328,000 | $0 | - | - |
| Payables And Accrued Expenses | $3,585,000 | $2,427,000 | $1,801,000 | $4,101,000 |
| Payables | $2,140,000 | $809,000 | $249,000 | $693,000 |
| Total Tax Payable | $261,000 | $0 | - | - |
| Accounts Payable | $1,879,000 | $809,000 | $249,000 | $693,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $9,996,000 | $3,391,000 | $10,012,000 | $41,881,000 |
| Total Equity Gross Minority Interest | $9,996,000 | $3,391,000 | $10,012,000 | $41,881,000 |
| Stockholders Equity | $9,996,000 | $3,391,000 | $10,012,000 | $41,881,000 |
| Retained Earnings | $-846,610,000 | $-844,823,000 | $-824,532,000 | $-785,324,000 |
| Preferred Securities Outside Stock Equity | $3,181,000 | $0 | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $1 | $0 | $0 | $0 |
| Ordinary Shares Number | $256,396 | $6,662 | $858 | $628 |
| Share Issued | $256,397 | $6,662 | $858 | $628 |
| Tangible Book Value | $-14,134,000 | $-21,859,000 | $-18,296,000 | $-5,871,000 |
| Invested Capital | $10,657,000 | $3,624,000 | $10,264,000 | $42,175,000 |
| Working Capital | $-3,143,000 | $1,383,000 | $4,920,000 | $18,568,000 |
| Capital Lease Obligations | $1,161,000 | $1,597,000 | $2,028,000 | $2,599,000 |
| Total Capitalization | $9,996,000 | $3,391,000 | $10,012,000 | $41,881,000 |
| Treasury Stock | $3,054,000 | $3,054,000 | $3,054,000 | $3,054,000 |
| Additional Paid In Capital | $859,660,000 | $851,268,000 | $837,598,000 | $830,259,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $653,000 | $1,161,000 | $1,624,000 | $2,071,000 |
| Current Capital Lease Obligation | $508,000 | $436,000 | $404,000 | $528,000 |
| Current Accrued Expenses | $1,445,000 | $1,618,000 | $1,552,000 | $3,408,000 |
| Net PPE | $1,162,000 | $1,627,000 | $2,115,000 | $3,392,000 |
| Accumulated Depreciation | $-3,825,000 | $-3,741,000 | $-3,658,000 | $-6,731,000 |
| Gross PPE | $4,987,000 | $5,368,000 | $5,773,000 | $10,123,000 |
| Leases | $2,664,000 | $2,664,000 | $2,649,000 | $2,649,000 |
| Other Properties | $1,051,000 | $1,444,000 | $1,853,000 | $2,381,000 |
| Machinery Furniture Equipment | $1,272,000 | $1,260,000 | $1,271,000 | $5,093,000 |
| Properties | $0 | $0 | $0 | $0 |
| Goodwill | - | $0 | $3,058,000 | $15,682,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-15,414,000 | $-13,452,000 | $-19,465,000 | $-23,943,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-15,402,000 | $-13,437,000 | $-19,452,000 | $-23,664,000 |
| Cash Flow From Continuing Operating Activities | $-15,402,000 | $-13,437,000 | $-19,452,000 | $-23,664,000 |
| Operating Gains Losses | $-25,338,000 | $9,000 | $-691,000 | $396,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-12,000 | $-15,000 | $-13,000 | $-279,000 |
| Investing Cash Flow | $-12,000 | $-15,000 | $197,000 | $-279,000 |
| Cash Flow From Continuing Investing Activities | $-12,000 | $-15,000 | $197,000 | $-279,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-1,876,000 | $0 | - | - |
| Issuance Of Capital Stock | $5,486,000 | $11,549,000 | $4,253,000 | $32,233,000 |
| Financing Cash Flow | $12,733,000 | $11,595,000 | $3,079,000 | $29,361,000 |
| Cash Flow From Continuing Financing Activities | $12,733,000 | $11,595,000 | $3,079,000 | $29,361,000 |
| Net Other Financing Charges | $8,523,000 | - | - | $1,000,000 |
| Cash Dividends Paid | $-657,000 | $0 | - | - |
| Preferred Stock Dividend Paid | $-657,000 | $0 | - | - |
| Net Preferred Stock Issuance | $-1,876,000 | $0 | - | - |
| Net Common Stock Issuance | $5,486,000 | $11,549,000 | $4,253,000 | $32,233,000 |
| Common Stock Issuance | $5,486,000 | $11,549,000 | $4,253,000 | $32,233,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-605,000 | $-797,000 | $-1,174,000 | $-3,872,000 |
| Issuance Of Debt | $1,862,000 | $0 | - | $0 |
| End Cash Position | $1,788,000 | $4,469,000 | $6,326,000 | $22,502,000 |
| Beginning Cash Position | $4,469,000 | $6,326,000 | $22,502,000 | $17,084,000 |
| Changes In Cash | $-2,681,000 | $-1,857,000 | $-16,176,000 | $5,418,000 |
| Proceeds From Stock Option Exercised | $0 | $843,000 | $0 | $0 |
| Preferred Stock Payments | $-1,876,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $1,257,000 | $-797,000 | $-1,174,000 | $-3,872,000 |
| Net Short Term Debt Issuance | $-455,000 | $-797,000 | $-1,174,000 | - |
| Short Term Debt Payments | $-455,000 | $-797,000 | $-1,174,000 | - |
| Net Long Term Debt Issuance | $1,712,000 | $0 | $-1,174,000 | $-3,872,000 |
| Long Term Debt Payments | $-150,000 | $0 | $-1,174,000 | $-3,872,000 |
| Long Term Debt Issuance | $1,862,000 | $0 | - | $0 |
| Net PPE Purchase And Sale | $-12,000 | $-15,000 | $197,000 | $-279,000 |
| Purchase Of PPE | $-12,000 | $-15,000 | $-13,000 | $-279,000 |
| Change In Working Capital | $1,371,000 | $2,018,000 | $-1,777,000 | $-58,000 |
| Change In Other Current Liabilities | $-977,000 | $469,000 | $-571,000 | $-548,000 |
| Change In Payables And Accrued Expense | $1,270,000 | $626,000 | $-2,282,000 | $-875,000 |
| Change In Accrued Expense | $200,000 | $66,000 | $-1,838,000 | $-407,000 |
| Change In Payable | $1,070,000 | $560,000 | $-444,000 | $-468,000 |
| Change In Account Payable | $1,070,000 | $560,000 | $-444,000 | $-468,000 |
| Change In Prepaid Assets | $1,078,000 | $923,000 | $1,076,000 | $1,365,000 |
| Other Non Cash Items | $8,681,000 | $409,000 | $528,000 | $1,171,000 |
| Stock Based Compensation | $455,000 | $1,278,000 | $3,086,000 | $7,238,000 |
| Unrealized Gain Loss On Investment Securities | $222,000 | $0 | - | - |
| Asset Impairment Charge | $1,120,000 | $3,058,000 | $19,444,000 | $45,020,000 |
| Deferred Tax | $-210,000 | $0 | $-1,367,000 | $-9,987,000 |
| Deferred Income Tax | $-210,000 | $0 | $-1,367,000 | $-9,987,000 |
| Depreciation Amortization Depletion | $84,000 | $82,000 | $533,000 | $192,000 |
| Depreciation And Amortization | $84,000 | $82,000 | $533,000 | $192,000 |
| Gain Loss On Investment Securities | $-10,563,000 | - | - | - |
| Net Foreign Currency Exchange Gain Loss | $-338,000 | $-3,000 | $-710,000 | $396,000 |
| Gain Loss On Sale Of PPE | $0 | $12,000 | $19,000 | $0 |
| Net Income From Continuing Operations | $-1,787,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 |
| Sale Of PPE | - | $0 | $210,000 | $0 |